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Severe aortic stenosis (AS) is common. Once symptomatic or left ventricular 
(LV) impairment develops, current guidelines recommend aortic valve replacement 
(AVR) to improve survival and symptom status.1 But the etiology of symptoms may 
be difficult to ascertain in the elderly with multiple co-morbidities, and indeed LV 
impairment may be late – occurring potentially after irreversible changes have 
occurred in the heart, which in turn may result in residual risk to patients even after 
AVR. The current focus of AS management remains the valve itself, however over 
the last decade there been increasing recognition of the importance of the 
myocardium. The stenosed valve is the insult – necessary, but perhaps not sufficient 
to cause the adverse consequences of AS.  How the myocardium responds is equally 
important and may determine the urgency of intervention.  The myocardium itself is 
adaptable – but there are limits. In response to afterload, early changes are benign and 
physiologically appropriate with myocardial cellular hypertrophy and proportionate 
extracellular matrix (ECM) expansion to maintain wall stress. However, the afterload 
of AS is proximal to the coronary origins so reduction of microvascular function start 
with reduced capillary density, compensatory vasodilation and impaired myocardial 
blood flow – so even if myocytes were infinitely adaptable, compensation through 
adaptation cannot be indefinite.2, 3 Further, increasingly maladaptive changes occur 
with cell death by apoptosis or autophagy, microvascular ischemia, alterations of 
ECM components (e.g. increased collagen I and III deposition),4 and the development 
of irreversible microscars particularly in the subendocardium. The combination of an 
increasingly precarious systemic circulation with its physiological autonomic 
adaptability lost, and myocardium, that is now heterogeneous, ischemic and 
arrhythmogenic, is dangerous. Arrhythmia becomes increasingly likely and 
intolerable due to hypoperfusion-related positive feedback. Many of the processes 
leading to these scenarios are detectable. Transvalvular gradients and by inference 
myocardial perfusion pressures, left ventricular hypertrophy (LVH) and cardiac 
function have long been measurable.  Cardiovascular magnetic resonance (CMR) 
adds extra information with late gadolinium enhancement (LGE) detecting focal 
fibrosis and T1 mapping for the derived parameter that is extracellular volume 
fraction (ECV), which reflects fibrosis burden and its reciprocal (1-ECV=ICV) 
reflecting the cell (mainly myocyte) volume.5, 6 These can be expressed either as 
proportions (ECV in %) or as absolute volumes if the ECV or ICV are multiplied by 
the myocardial volume; this matrix volume or iECV is therefore obtained by the 
simple equation of LVM/1.05*ECV (1.05 being the specific gravity of the 
myocardium). With this armamentarium at our disposal, we can now better 
interrogate the biology of LVH.7, 8  
In the current issue, Everett et al9 report serial imaging using the above 
methods in two cohorts of patients with AS – one asymptomatic group (mild, 
moderate or severe AS) under a watchful-waiting regimen and one symptomatic 
group undergoing surgical AVR.  What they found was that without intervention, the 
AS severity progressed (by peak velocity and valve area), with increased filling 
pressures.  Myocardial changes were: a decrease in longitudinal function, increased 
hypertrophy (wall thickness, mass) and, importantly, increased amounts of focal 
fibrosis (LGE). Indeed, there appeared to be an acceleration in AS progression, 
coupled with scar number and extent. Diffuse fibrosis remained in proportion to cell 
volume during this phase, however. In the cohort of patients undergoing AVR, LV 
mass regression did occur due to a reduction in both myocyte and interstitial volume 
(by the ECV technique) – both parameters demonstrating plasticity and reversibility, 
but with the cellular hypertrophy regression more (so the ECV rose post AVR). Scar 
however did not reverse.    
The authors should be lauded for delivering a well-conducted cross-sectional two 
center CMR AS study, with all the challenges of using different MRI field strengths 
and sequence parameters. The multiparametric approach (LGE and ECV imaging) in 
the current study provides important pathophysiological insight into the natural 
history of LV remodeling in AS. The postoperative data confirm the results of the 
RELIEF-AS Study (NCT02174471) demonstrating in 116 patients at 1-year post-
AVR a 19% regression in indexed LV mass, 16% reduction in matrix volume and a 
proportionally greater 22% reduction in cell volume with focal fibrosis being 
irreversible.8 What is new is the insights into the accumulation over time of LGE – 
with its near absence in mild AS (with minimal annual change), but increasing 
accumulation with moderate and severe AS. We know that small amounts of LGE in 
AS reflect much larger changes in the myocardium – indeed patients with severe AS 
and LGE on CMR have 1000s of microscars, with a subendocardial preponderance 
and marked thickening of the endocardium4, 10, 11 coupled with alterations in the 
qualitative nature of the fibrosis, its maturity, tensile properties and collagen subtypes.  
There may in addition be other processes at play.  LGE represents focal interstitial 
water, usually fibrosis but it can also be inflammation or amyloid. One recent AVR 
study showed a 6% prevalence of wild type ATTR amyloidosis at biopsy12 and two 
recent studies have shown a prevalence of 1 in 7 using bone scintigraphy in (older) 
patients undergoing transcatheter aortic valve replacement13, 14   
Does this matter, and how can we use these insights to improve patient care? 
Judicious timing of surgical or transcatheter intervention is likely to lead to better 
outcomes. Intervening too early front-loads procedural risk, in some cases may be un-
necessary and may expose patients to on-going risk (anticoagulation, endocarditis, 
valve failure). Conversely, watchful waiting risks the loss of some patients from 
sudden death, the conversion of elective surgery in stable patients to salvage surgery 
in decompensation, and, importantly, the potential accrual by patients of risk or 
limitation that persists post procedure.   There is emerging evidence for this concept 
of residual risk and of the consequences of delay. Some patients without overt 
symptoms may be reluctant to undergo surgery, but we need to be careful and look at 
long-term outcomes.  In the CURRENT AS registry, 3 year mortality was 9% in 
patients who had early AVR compared to 17.9% in propensity-matched patients who 
were initially managed conservatively.15 Acute decompensation in watchful waiting 
strategies is increasingly recognised,16 and the recently presented AS700 multicenter 
study suggested that the presence of myocardial scar (present in half of patients with 
severe AS undergoing AVR) was associated with a doubling of death rates and 3.5 
years – the full paper is awaited.  New approaches are being explored.17 The 
EVOLVED-AS study (NCT03094143) is currently recruiting to investigate whether 
we can reduce the incidence of heart failure and death by timing intervention based on 
the presence of scar by MRI, troponin elevation or adverse ECG changes prior to the 
development of symptoms.  
Finally, we remind that although the CMR cell-versus-matrix approach 
appears relatively new, we acknowledge the pioneering work of Franz Schwarz and 
colleagues in 1978 who used invasive biopsy to divide LVH into cellular and fibrotic 
components in AS – in the era of CMR we can now reveal the dynamic changes and 
track response to therapy.10 But really this is not about CMR or techniques – it’s 
about patients. We need to think about aortic stenosis as a disease of the myocardium 
where we should be seeking to avoid irreversible ‘AS cardiomyopathy’ – and, if that 
is unavoidable (first presentation being late in many patients), consider strategies after 
valve replacement to mitigate residual risk.  These approaches may, given how 
common AS is, yield great improvements in patient outcomes.   
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